Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology Alliance develops and conducts cancer clinical trials as part of NCI National Clinical Trials Network

Follow us on Twitter!
- www.twitter.com/ALLIANCE_Org/

🚀 New Trial Now Enrolling! 🌟Angela Bradbury, MD of is leading Alliance A232301CD, a study exploring whether a 💬 digital...
08/14/2026

🚀 New Trial Now Enrolling! 🌟
Angela Bradbury, MD of is leading Alliance A232301CD, a study exploring whether a 💬 digital chatbot intervention can be as effective as 📡 standard remote genetic services in increasing counseling uptake among adolescent and young adult cancer patients. 🔗 Learn more: https://bit.ly/AllianceA232301CD

🤝 Now Enrolling: Neoadjuvant Immunotherapy Trial for Sarcomatoid MesotheliomaFor patients diagnosed with resectable non-...
08/14/2026

🤝 Now Enrolling: Neoadjuvant Immunotherapy Trial for Sarcomatoid Mesothelioma
For patients diagnosed with resectable non-epithelioid or sarcomatoid pleural mesothelioma, early treatment strategy is crucial.
Alliance A082101 (Led by Aaron Mansfield, MD, of the Mayo Clinic,) is currently recruiting eligible adult patients to evaluate the safety and clinical benefit of administering dual immunotherapy (nivolumab + ipilimumab) prior to surgical resection.
Key Trial Highlights:
• Study Goal: Determine the rate of successful surgical completion and 12-month progression-free survival following neoadjuvant dual checkpoint blockade.
• Patient Population: Stage I-IIIa resectable non-epithelioid/sarcomatoid-dominant pleural mesothelioma.
• Study Type: NCI-sponsored Phase II multicenter trial.
By mobilizing the immune system before surgery, this approach seeks to reduce recurrence risk and improve overall outcomes for a historically hard-to-treat cancer.
Please share this opportunity with colleagues, patients, and advocacy networks who may benefit from new therapeutic avenues in thoracic oncology.
đź”— Trial Details & Enrollment Locations:
https://bit.ly/Alliance-A082101

Alliance SOLARIS Trial: Vitamin D3 Fails to Boost Colorectal Cancer SurvivalFor patients with advanced colorectal cancer...
08/13/2026

Alliance SOLARIS Trial: Vitamin D3 Fails to Boost Colorectal Cancer Survival

For patients with advanced colorectal cancer, adding high-dose vitamin D3 to standard first-line treatment does not improve progression-free survival, according to the results from the Alliance Phase III SOLARIS trial published in the JAMA.

Key takeaways
• Main result: Patients who received high-dose vitamin D3 had a median progression-free survival of 11.8 months, compared with 10.3 months for those who received standard-dose vitamin D3. This difference was not statistically significant.
• Overall survival and tumor response: Overall survival was also similar between the groups (25.6 months vs. 27.0 months), as were objective response rates (51% vs. 44%). Neither difference was statistically significant.
• Safety and tolerability: High-dose vitamin D3 was generally well tolerated when given with standard treatment. Vitamin D-related complications, such as high blood calcium and kidney stones), were rare, with no significant difference between the treatment groups.
• Vitamin D levels: The high-dose vitamin D3 regimen successfully increased participants' vitamin D blood levels into the target range.

“While we are disappointed that high-dose vitamin D3 did not improve overall outcomes in patients with metastatic colorectal cancer, these definitive findings provide clear guidance for oncology clinicians and patients navigating treatment decisions,” said lead author Kimmie Ng, MD, MPH, Professor of Medicine at Harvard Medical School, Associate Chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute (DFCI), and the Founding Director of the Young-Onset Colorectal Cancer Center at DFCI.

Read the Alliance news story at: https://bit.ly/SOLARIS-trial
Read the JAMA article at: https://bit.ly/SOLARIS-JAMA

Do you know an individual whose behind-the-scenes efforts have made a profound impact on oncology clinical trials?Nomina...
08/13/2026

Do you know an individual whose behind-the-scenes efforts have made a profound impact on oncology clinical trials?
Nominations are now open for the 2026 Richard L. Schilsky CALGB Achievement Award, presented by the Alliance for Clinical Trials in Oncology.
This award honors the "unsung heroes" of cancer research—individuals whose leadership, dedication, and service have strengthened cooperative group clinical research and advanced patient care.
Past recipients include:
• Dr. Richard M. Stone (Dana-Farber Cancer Institute, 2025)
• Dr. Richard Goldberg (West Virginia University Cancer Institute, 2024)
• Dr. Jeffrey Crawford (Duke Cancer Institute, 2023)
• Dr. M. Margaret (Peggy) Kemeny (Queens Hospital Center, 2021)

All Alliance members are invited to submit nominations by Friday, August 28, 2026.
Learn more about the nomination criteria and process at https://bit.ly/Schilsky26

New Phase III Trial Launches to Evaluate Immunotherapy in Early Lung CancerThe Alliance for Clinical Trials in Oncology ...
08/13/2026

New Phase III Trial Launches to Evaluate Immunotherapy in Early Lung Cancer
The Alliance for Clinical Trials in Oncology has launched a new national phase III study (Alliance A082302) to evaluate if administering the immunotherapy drug atezolizumab
immediately after surgery reduces the risk of cancer recurrence in patients with stage I non-small cell lung cancer ( ).
Currently, standard post-surgical care for most stage I NSCLC patients involves close monitoring through regular scans and checkups (observation) rather than active drug therapy. This randomized trial aims to enroll 336 participants across two comparison groups:
• Observation: Standard follow-up care (regular checkups and scans) with no additional anti-cancer treatment.
• Immunotherapy: Standard follow-up care plus atezolizumab, which utilizes the body's immune system to identify and eliminate remaining cancer cells.
Led by Muhammad Furqan, MD, of the University of Oklahoma Stephenson Cancer Center, the objective of the study is to determine if early intervention with immunotherapy post-surgery provides a statistical benefit over standard observation alone for patients with early-stage disease.
More at https://bit.ly/43SStJU.

💗 Advancing Quality of Life for Breast Cancer Survivors 💗Breast cancer survivorship is about more than beating cancer—it...
08/12/2026

đź’— Advancing Quality of Life for Breast Cancer Survivors đź’—
Breast cancer survivorship is about more than beating cancer—it’s about living well afterward. A new national clinical trial, REVITALIZE, led by the Alliance for Clinical Trials in Oncology and supported by the National Cancer Institute, is taking on a common but often overlooked long term side effect: chronic vaginal dryness caused by breast cancer treatments.
🔬 What the trial is studying:
REVITALIZE is a randomized, placebo controlled study testing whether vaginal fractional CO₂ laser therapy can safely relieve moderate to severe symptoms in breast cancer survivors—especially those who cannot use estrogen based treatments.
👩‍⚕️ Why it matters:
➡️ Symptoms can persist for years
➡️ They significantly affect comfort, intimacy, and overall well being
➡️ High quality clinical evidence in this area is limited
✨ As survival rates continue to rise, research like this reflects an important shift in oncology: prioritizing survivorship, supportive care, and patient reported outcomes with the same rigor as cancer treatment itself.
Learn more at https://bit.ly/REVITALIZE2026

With colorectal cancer, an inherited gene change doesn’t just impact one person — it can affect an entire family. 👨‍👩‍👧‍...
08/12/2026

With colorectal cancer, an inherited gene change doesn’t just impact one person — it can affect an entire family. 👨‍👩‍👧‍👦 When one individual carries a hereditary risk, parents, siblings, and children may also face a higher chance of developing the disease, making early detection and preventive care essential. 🩺
Led by Frank Sinicrope, MD, of the Mayo Clinic and Heather Hampel, MS, of City of Hope Cancer Center, a new study, Alliance A212101, is exploring whether family members are more likely to get genetic testing when they hear about their potential risk directly from a healthcare provider. 🧬 Early testing can lead to earlier action — and potentially save lives. 💙
đź”— Learn more: https://bit.ly/CRCGene-Testing

🔬 Precision Medicine in Neuro-Oncology: Alliance A071401 Trial Enrolling PatientsAddressing genomic drivers in central n...
08/11/2026

🔬 Precision Medicine in Neuro-Oncology: Alliance A071401 Trial Enrolling Patients
Addressing genomic drivers in central nervous system tumors remains a critical frontier in cancer research. Led by Priscilla Brastianos, MD, of Mass General, this study is recruiting patients to evaluate the efficacy of genomic-matched targeted therapies in progressive or recurrent meningiomas.
Key Trial Highlights:
• Study Design: Phase II biomarker-driven, multi-arm clinical trial.
• Targeted Pathways: Evaluates specific genetic alterations using targeted treatments including Hedgehog inhibitors (vismodegib), AKT inhibitors (capivasertib), CDK4/6 inhibitors (abemaciclib), and FAK inhibitors.
• Objective: Determine progression-free survival and overall response rates across specific molecularly defined cohorts.
Help spread the word to clinicians and researchers navigating care options for patients with recurrent meningioma.
đź“„ Full protocol, participating sites, and contact information:
https://bit.ly/A071401-trial

Now enrolling! The Alliance for Clinical Trials in Oncology has a new study focused on rare adrenal cancers, including a...
08/11/2026

Now enrolling! The Alliance for Clinical Trials in Oncology has a new study focused on rare adrenal cancers, including adrenocortical carcinoma and advanced pheochromocytoma/paraganglioma. These aggressive tumors often lack effective treatment options, making this research critical for patients and clinicians alike.
What’s unique about this trial?
âś… It explores targeted therapies designed to attack specific molecular pathways driving these cancers.
âś… The study leverages precision medicine to match patients with treatments based on tumor biology.
âś… It aims to improve outcomes for patients facing limited options today.
This trial reflects the Alliance’s commitment to addressing unmet needs in oncology and advancing care for rare cancers through collaborative, patient-centered research.
đź”— Learn more about the study and eligibility: https://bit.ly/A092204-Konda

Address

Alliance For Clinical Trials In Oncology, Alliance Operations, 311 S. Wacker Drive, Suite 2650
Chicago, IL
60606

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+16177328919

Website

Alerts

Be the first to know and let us send you an email when Alliance for Clinical Trials in Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category